Inventiva SA ADR ( (IVA) ) has released its Q4 earnings. Here is a breakdown of the information Inventiva SA ADR presented to its investors.
Inventiva SA ADR is a clinical-stage biopharmaceutical company specializing in the development of oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs.
In its 2024 earnings report, Inventiva highlighted a pivotal year marked by significant advancements in its clinical trials, particularly the NATiV3 Phase 3 trial for lanifibranor, alongside securing substantial structured financing to support ongoing and future developments.
The company reported revenues of €9.2 million for 2024, with cash and cash equivalents at €96.6 million by year-end. A structured financing deal closed with gross proceeds of €116 million, and a pipeline prioritization plan was announced to focus exclusively on lanifibranor, resulting in a 50% workforce reduction. Research and development expenses decreased by 17% to €90.9 million, primarily due to a temporary pause in patient recruitment for the NATiV3 trial.
Despite a net loss of €184.2 million for the year, Inventiva’s financial activities generated €145.6 million, significantly boosting its cash position. The company aims to finance its operations until the third quarter of 2025, with expectations of further funding from the second tranche of structured financing and milestone payments.
Looking ahead, Inventiva remains focused on advancing its lanifibranor program, with the completion of patient enrollment in the NATiV3 trial expected in the first half of 2025 and topline results anticipated in the second half of 2026, positioning the company for potential regulatory submissions and commercialization opportunities.